19 hrs ago
Cubist Pharmaceuticals Given "Neutral" Rating at Zacks
's stock had its "neutral" rating restated by Zacks in a report released on Tuesday, ARN reports.
Trending on the Topix Network
Thu Mar 06, 2014
Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
The Company will not hold a quarterly conference call to discuss these results given the proximity to the scheduled announcement in late March of top-line results from its phase 2 clinical trial with ARIKAYCEA to treat nontuberculous mycobacteria lung infections.
Thu Feb 27, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
The event will take place in Tulsa's Brady Arts District July 25... )--Powerhouse Dynamics announces a major expansion of the remote equipment control functionality of its award-winning enterprise energy and asset management system, SiteSage --Fitch Ratings has updated its sector criteria report for rating general obligations of state housing ... (more)
Cubist announces EMA acceptance of Tedizolid MAA for review
Cubist announces EMA acceptance of Tedizolid MAA for review Cubist Pharmaceuticals announced that the European Medicines Agency has accepted for review the company's Marketing Authorization Application, or MAA, for its investigational antibiotic tedizolid phosphate.
Wed Feb 26, 2014
Moody's sees revenue ramp, not cliff, from biosimilar competition
A recent report from Moody's says launches of biosimilars - generic versions of complex biologics drugs - in the U.S. are likely at least three years away.
Fri Feb 21, 2014
Cubist Pharmaceuticals CEO Sells $235,267 in Stock
Cubist Pharmaceuticals CEO Michael W. Bonney sold 3,112 shares of the company's stock in a transaction dated Thursday, February 20th.
Thu Feb 13, 2014
Cubist & Cambridge Science Festival Launch "Germ Challenge" Science Contest
LEXINGTON, Mass. & CAMBRIDGE, Mass. -- -- Cambridge Science Festival and Cubist Pharmaceuticals, Inc. today launched the 2014 "Germ Challenge," a contest designed to engage young people in science by inviting them to create educational and creative videos that demonstrate their knowledge of germs and their ability to communicate scientific concepts ... (more)
Tue Feb 11, 2014
Fecal Transplants Might Become A Threat For Cubist's Fidaxomicin Sales And The CVR
Last October Cubist Pharmaceuticals bought Optimer. Optimer had one drug: fidaxomicin, sold in the US as DIFICID.
Mon Feb 10, 2014
Cubist to Present at February Investor Conferences
Cubist Pharmaceuticals, Inc. today announced that company management will discuss the company's business activities, financial outlook, at the 2014 RBC Capital Markets' Global Healthcare Conference in February.